Application
Time-resolved fluorescene (TRF) reagent for assays of the cytotoxic activity of immune effector cells against tumor cells (including ones which are opsonized with antibodies).
Advantages
- Non-RI small molecule
- Lower background level
- Shorter measurement time
Technology Overview & Background
A novel non-RI reagent for TRF with highly maximum release and lower spontaneous release from cell. This molecule is more potent than well-known chelating lanthanide-labeled TRF reagent.
When the tumor cells are pretreated with this novel pro-chelate-forming compound, its hydrolyzate is released upon disruption of the tumor cell membrane during the cellular killing. Upon addition of Europium (Eu), the cellular cytotoxicity can be determined by TRF within very short measuring time (30–40 min.).
Publications
Sakai Y., Tanaka Y., et al. “Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells.”
ChemMedChem 2017; 12(23): 2006–2013.
[DOI] 10.1002/cmdc.201700626.
Patents
Issued in Japan (JP 6501271), Europe (EP 3127899) and the United States (US 10175229).
Principal Investigator
Yoshimasa TANAKA, PhD (Professor, Nagasaki University, Japan)
Expectations
TECH MANAGE is looking for both biotech companies to develop this technology and sell products for research use, and pharmaceutical companies and CDMOs to use for the evaluation for their clinical purposes (i.e. for cell therapy-related products).
Project ID: JT-00546